Sanofi’s CEO Quits Diabetes as Cancer Breakthroughs Beckon
- French drugmaker to stop heart disease and diabetes research
- Hudson looks for fields with best returns after Synthorx deal
This article is for subscribers only.
Sanofi’s new chief executive, just three months into the job, is taking a scalpel to traditional areas of research to rejuvenate the sluggish French drugmaker.
The pharma giant will end its hunt for new diabetes and heart disease drugs, helping save more than $2 billion as Paul Hudson favors fields like cancer that are ripe for innovation. Hudson, who took the helm in September, is set to outline his strategy to investors for the first time on Tuesday.